# 510(k) Summary of Safety and Effectiveness

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter Name, Address, and Contact:

Lin-Zhi International, Inc. 670 Almanor Avenue Sunnyvale, CA 94085 Phone: (408) 732-3856 Fax: (408) 732-3849 e-mail: bclin@lin-zhi.com

Contact: Bernice Lin, Ph.D. VP Operations

# Device Name and Classification

Classification Name:

Enzyme Immunoassay, Oxycodone Class II, DJG (91 Toxicology), 21 CFR 862.3650

Drug Specific Calibrators, Class II, DLJ (91 Toxicology), 21 CFR 862.3200

Drug Specific Controls, Class I, LAS (91 Toxicology), 21 CFR 862.3280

Common Name: Proprietary Name:

Homogeneous Oxycodone Enzyme Immunoassay LZI Oxycodone Enzyme Immunoassay, LZI Oxycodone Drugs of Abuse (DAU) Calibrators LZI Oxycodone Drugs of Abuse (DAU) Controls

# Legally Marketed Predicate Device(s)

The LZI Oxycodone Enzyme Immunoassay (EIA) is substantially equivalent to the Lin-Zhi International, Inc. Oxycodone Enzyme Immunoassay (k050733) manufactured by Lin-Zhi International, Inc. The LZI Oxycodone Enzyme Immunoassay is identical or similar to its predicate in terms of intended use, method principle, device components, and clinical performance.

# Device Description

The LZI Oxycodone assay is a homogeneous enzyme immunoassay with ready-to-use liquid reagents. The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity. In the absence of drug in the sample, oxycodone-labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. On the other hand, when free drug is present in the sample, antibody would bind to free drug; the unbound oxycodone-labeled G6PDH then exhibits its maximal enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at $3 4 0 ~ \mathrm { { n m } }$ .

The LZI Oxycodone Enzyme Immunoassay is a kit comprised of two reagents, an $\mathbf { R } _ { 1 }$ and ${ \mathrm { R } } _ { 2 }$ which are bottled separately but sold together within the kit.

The $\mathbf { R _ { l } }$ solution contains mouse monoclonal anti-Oxycodone antibody, glucose-6-phosphate (G6P) nicotinamide adenine dinucleotide (NAD), stabilizers, and sodium azide $( 0 . 0 9 \% )$ as a preservative. The ${ \bf R } _ { 2 }$ solution contains glucose-6-phosphate dehydrogenase (G6PDH) labeled with oxycodone in buffer with sodium azide $( 0 . 0 9 \% )$ as preservative.

The LZI Oxycodone Enzyme Immunoassay (k050733) calibrators and controls designated for use at the 100 and $3 0 0 ~ \mathrm { n g / m L }$ cutoffs contain 0, 50, 75, 100, 125,225, 300, 375, 500, and 800 $\mathfrak { n g } / \mathrm { m L }$ of oxycodone in human urine with sodium azide $( 0 . 0 9 \% )$ as preservative. These six calibrators and four controls are sold as individual bottles.

# Intended Use

The LZI Oxycodone Enzyme Immunoassay is intended for the qualitative and semiquantitative determination of Oxycodone in human urine at the cutoff values of 100 and 300 ng/mL. The assay is designed for professional use with a number of automated clinical chemistry analyzers.

The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GCMS and LCMS or (2) permitting laboratories to establish quality control procedures.

The LZI Oxycodone Drugs of Abuse (DAU) Calibrators are for use as calibrators in the qualitative and semi-quantitative calibration of the LZI Oxycodone Enzyme Immunoassay at the cutoff values of 100 and $3 0 0 ~ \mathrm { n g / m L }$ .

The LZI Oxycodone Drugs of Abuse (DAU) Controls are for use as assayed quality control materials to monitor the precision of the LZi Oxycodone Enzyme Immunoassay at the cutoff value of 100 and $3 0 0 ~ \mathrm { { n g / m L } }$ .

The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or liquid chromatography/mass spectrometry (GC/MS or LC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

# Comparison to Predicate Device

The LZI Oxycodone Enzyme Immunoassay is substantially equivalent to the Lin-Zhi International, Inc. Oxycodone Enzyme Immunoassay, Calibrators and Controls for Hitachi 717 Systems cleared by the FDA under the premarket notification $\mathbf { k } 0 5 0 7 3 3$ for its stated intended use.

The following table compares LZI's Oxycodone Enzyme Immunoassay with the predicate device.   

<table><tr><td rowspan=1 colspan=1>DeviceCharacteristics</td><td rowspan=1 colspan=1>Subject DeviceLZI Oxycodone Enzyme Immunoassay,Calibrators and Controls</td><td rowspan=1 colspan=1>Predicate Device (k050733)LZI Oxycodone Enzyme Immunoassay,Calibrators and Controls</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The LZI Oxycodone EnzymeImmunoassay, when used in conjunctionwith Hitachi 717 automated clinicalsystem analyzers, is intended for thequalitative and semi-quantitativedetermination of oxycodone and.oxymorphone in human urine at cutoffvalues of 100 or 300 ng/mL. The assay isdesigned for professional use with anumber of automated clinical chemistryanalyzers.This assay provides a rapid screening procedurefor determining the presence of oxycodone andoxymorphone in urine. The assay provides only apreliminary analytical result. A more specificalternative chemical method must be used in orderto obtain a confirmed analytical result. Gas orliquid chromatography/mass spectrometry (GC/MSor LC/MS) is the preferred conflrmatory method.Clinical consideration and professional judgmentshould be exercised with any drug of abuse testresult, particularly when the preliminary test resultis positive.</td><td rowspan=1 colspan=1>The LZI Oxycodone EnzymeImmunoassay, when used in conjunctionwith Hitachi 717 automated clinicalsystem analyzers, is intended for thequalitative and semi-quantitativedetermination of oxycodone andoxymorphone in human urine at cutoffvalues of 100 or 300 ng/mL. The assay isdesigned for professional use with anumber of automated clinical chemistryanalyzers.This assay provides a rapid screening procedurefor determining the presence of oxycodone andoxymorphone in urine. The assay provides only apreliminary analytical result. A more specificalternative chemical method must be used in orderto obtain a confirmed analytical result. Gas orliquid chromatography/mass spectrometry (GC/MSor LC/MS) is the preferred confirmatory method.Clinical consideration and professional judgmentshould be exercised with any drug of abuse testresult, particularly when the preliminary test resultis positive.</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Oxycodone</td><td rowspan=1 colspan=1>Oxycodone</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>100 or 300 ng/ml</td><td rowspan=1 colspan=1>100 or300 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Urine</td></tr><tr><td rowspan=1 colspan=1>CalibratorsLevel</td><td rowspan=1 colspan=1>0, 50, 100, 300, 500, and 800ng/mL</td><td rowspan=1 colspan=1>100 ng/mL Cutoff: 5 Levels(0, 75, 100, 225, 300 ng/mL)300 ng/mL Cutoff: 5 Levels(0, 100, 300, 500, 800 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Controls Level</td><td rowspan=1 colspan=1>100 ng/mL Cutoff: 2 Levels(75 ng/mL, 125 ng/mL)300 ng/mL Cutoff: 2 Levels(225 ng/mL, 375 ng/mL)</td><td rowspan=1 colspan=1>100 ng/mL Cutoff: 2 Levels(75 ng/mL, 125 ng/mL)300 ng/mL Cutoff: 2 Levels(225 ng/mL, 375 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2-8 °C until expiration date</td><td rowspan=1 colspan=1>2-8 °C until expiration date</td></tr></table>

# Performance Characteristics Summary: 100 ng/mL Cutoff Hitachi 717 Analyzer

Precision: $\mathbf { 1 0 0 n g / m L }$ Cutoff Semi-Quantitative Positive/Negative Results:

<table><tr><td rowspan=1 colspan=2>100 ng/mL Cutoff Result:</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>SampleConcentration</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>-100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>25 ng/mL</td><td rowspan=1 colspan=1>-75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>50 ng/mL</td><td rowspan=1 colspan=1>-50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>-25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>100 ng/mL</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>9 Pos/13 Neg</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>39 Pos/49 Neg</td></tr><tr><td rowspan=1 colspan=1>125 ng/mL</td><td rowspan=1 colspan=1>+25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>+50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>175 ng/mL</td><td rowspan=1 colspan=1>+75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>200 ng/mL</td><td rowspan=1 colspan=1>+100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

Qualitative Positive/Negative Results:   

<table><tr><td rowspan=1 colspan=2>100 ng/mL Cutoff Result:</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>SampleConcentration</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>-100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>25 ng/mL</td><td rowspan=1 colspan=1>-75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>50 ng/mL</td><td rowspan=1 colspan=1>-50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>-25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>100 ng/mL</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>6 Pos/ 16 Neg</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>25 Pos/63 Neg</td></tr><tr><td rowspan=1 colspan=1>125 ng/mL</td><td rowspan=1 colspan=1>+25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>+50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>175 ng/mL</td><td rowspan=1 colspan=1>+75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>200 ng/mL</td><td rowspan=1 colspan=1>+100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

Precision: ${ \bf 3 0 0 n g / m L }$ Cutoff Semi-Quantitative Positive/Negative Results:   

<table><tr><td rowspan=1 colspan=2>300 ng/mL Cutoff Result:</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>SampleConcentration</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>-100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>-75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>-50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>225 ng/mL</td><td rowspan=1 colspan=1>-25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>3 Pos/ 19 Neg</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>26 Pos/ 62 Neg</td></tr><tr><td rowspan=1 colspan=1>375 ng/mL</td><td rowspan=1 colspan=1>+25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>450 ng/mL</td><td rowspan=1 colspan=1>+50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>525 ng/mL</td><td rowspan=1 colspan=1>+75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>600 ng/mL</td><td rowspan=1 colspan=1>+100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

Precision: ${ \bf 3 0 0 n g / m L }$ Cutoff Continued Qualitative Positive/Negative Results:   

<table><tr><td rowspan=1 colspan=2>300 ng/mL Cutoff Result:</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>SampleConcentration</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>-100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>-75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>-50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>225 ng/mL</td><td rowspan=1 colspan=1>-25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>1 Pos/21 Neg</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>23 Pos/65 Neg</td></tr><tr><td rowspan=1 colspan=1>375 ng/mL</td><td rowspan=1 colspan=1>+25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>450 ng/mL</td><td rowspan=1 colspan=1>+50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>525 ng/mL</td><td rowspan=1 colspan=1>+75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>600 ng/mL</td><td rowspan=1 colspan=1>+100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

# Performance Characteristics Summary: 100 & 300 ng/mL Cutoff

Hitachi 717 Analyzer

Linearity: 100 & ${ \bf 3 0 0 n g / m L }$ Cutoff   
Hitachi 717 Instrument: $\mathbf { 0 . 8 0 0 \ n g / m L }$   
When comparing the result (y) and target $( \mathbf { x } )$ value, using the least squares regression   
technique, the regression equation and correlation are as follows:   
y = 0.974x + 1.4518, r2 = 0.998   
Method Comparison - Clinical Samples: $\mathbf { 1 0 0 \ n g / m L }$ Cutoff   
From a total of eighty-nine (89) clinical unaltered samples:   
Semi-Quantitative & Qualitative Data: 93.75% agreement with positive, 100.0%   
agreement with negative samples

Method Comparison - Clinical Samples: $\mathbf { 3 0 0 n g / m L }$ Cutoff

From a total of one-hundred and one (101) clinical unaltered samples: Semi-Quantitative & Qualitative Data: 96.1% agreement with positive, 98.0% agreement with negative samples

Endogenous Compouind Interference & Specificity & Cross-Reactivity: No significant undesired cross-reactants or endogenous substance interference was observed.

# Summary:

The information provided in this pre-market notification demonstrates that the LZl Oxycodone Enzyme Immunoassay is substantially equivalent to the legally marketed predicate device for its general intended use. Substantial equivalence was demonstrated through comparison of intended use and physical properties to the commercially available predicate device as confirmed by chromatography/mass spectrometry (GC/MS or LC/MS), an independenit analytical method. The information supplied in this premarket notification provides reasonable assurance that the LZI Oxycodone Enzyme Immunoassay is safe and effective for its stated intended use.

Lin-Zhi International, Inc c/o Bernice Lin, Ph.D. 670 Almanor Avenue Sunnyvale, CA 94085

Re: k120763 Trade Name: LZI Oxycodone Enzyme Immunoassay LZI Oxycodone Drugs of Abuse (DAU) Calibrators, LZI Oxycodone Drugs of Abuse (DAU) Controls Regulation Number: 21 CFR $\ S 8 6 2 . 3 6 5 0$ E Regulation Name: Opiate test system Regulatory Class: Class II Product Codes: DJG, DLJ, LAS Dated: April 27, 2012 Received: April 30, 2012

Dear Dr. Lin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/Medical   
Devices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance...

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm

Sincerely yours,

![](images/d43f3b05b5685a6bab9e8ac69c9f9db181f16f1bbd33de7b8cbf2b65122b8cab.jpg)

Couptney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Premarket Notification

# Indications for Use Statement

510(k) Number (if known): k/20763

Device Name: LZI Oxycodone Enzyme Immunoassay

# Indications for Use:

The LZl Oxycodone Enzyme Immunoassay is intended for the qualitative and semiquantitative determination of Oxycodone in human urine at the cutoff values of 100 and 300 $\mathrm { n g / m L }$ . The assay is designed for professional use with a number of automated clinical chemistry analyzers.

The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GCMS and LCMS or (2) permitting laboratories to establish quality control procedures.

The LZI Oxycodone Drugs of Abuse (DAU) Calibrators are for use as calibrators in the qualitative and semi-quantitative calibration of the LZI Oxycodone Enzyme Immunoassay.

The LZI Oxycodone Drugs of Abuse (DAU) Controls are for use as assayed quality control materials to monitor the precision of the LZI Oxycodone Enzyme Immunoassay.

The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or liquid chromatography/mass spectrometry. (GC/MS or LC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

Prescription Use_ AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D). (21 CFR 807 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD) (Per 21 CFR 801.109) Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety Page of 1 510(k) K120763